© 2021 Copyright France 24 – All rights reserved. France 24 is not responsible for content from external websites. Attendance certified by the ACPM / OJD.
The Franco-Austrian laboratory Valneva announced on Monday that it had “received a notice of termination” from the British government concerning “the supply agreement” of its candidate vaccine against Covid-19, in a press release.
“The contract includes a clause allowing the British government to terminate it. It further claims that Valneva failed in its obligations, which Valneva vigorously contests”, indicates, without further details, the laboratory to which the United Kingdom had ordered 100 million doses for 2021-2022.
Valneva uses a vaccine with deactivated virus, a technology more traditional than the RNA, and which is used in particular for the vaccines against the flu each year. He had submitted his request for authorization to the British health authorities in August.
The laboratory had indicated at the end of August that on the basis of the phase I and II trials, it hoped “to have a vaccine which is more than 80% effective”. “This will have to be demonstrated in the phase III trial”, underlined its managing director Franck Grimaud.
“Valneva has worked tirelessly, and invested to the maximum of his ability, in working with” the British government, “including committing significant resources and showing a very strong commitment to meet [his] demands on vaccines adapted to variants, “highlights the laboratory on Monday.
He indicates that he “continues to be fully engaged in the development” of his vaccine candidate, VLA2001, and that he “will increase his efforts with other potential customers to ensure that his inactivated vaccine can be used in the fight against the pandemic “.
Valneva recalls that the results of phase III trials – intended to prove the real effectiveness of a treatment before a possible marketing – “are expected at the beginning of the fourth quarter”.
These results “will be part of the progressive submission of the VLA2001 conditional authorization application package to the UK Health Agency. Subject to Phase III results and UK Health Agency approval,” Valneva believes that an initial marketing authorization for VLA2001 could be obtained by the end of 2021 “.